Abstract
Eosinophilic annular erythema (EAE) is a rare eosinophilic dermatosis with few documented cases in the literature. It is considered either a distinct entity or subtype of Well’s syndrome (eosinophilic cellulitis), but EAE, in contrast to Well’s syndrome, is characterized by a chronic course and resistance to treatment. Therapies with reported efficacy include anti-malarial medications, suplatast tosilate, and dapsone. We report the first adult case of EAE to respond to dupilumab, an IL-4 receptor antagonist, which targets the type 2 inflammatory response associated with tissue eosinophilia.
Highlights
Eosinophilic annular erythema (EAE) is a rare eosinophilic dermatosis characterized by resistance to treatment and high rate of relapse.[1]
We report a case of EAE responsive to the IL-4 receptor antagonist, dupilumab
EAE was first described in the literature in 1999 as a “gyrate erythema” distinct from Well’s syndrome due to the lack of blood eosinophilia and “flame figures,” deposits of eosinophil basic protein mixed with degenerated collagen fibers, which are both characteristic findings in Well’s syndrome.[2]
Summary
Eosinophilic annular erythema (EAE) is a rare eosinophilic dermatosis characterized by resistance to treatment and high rate of relapse.[1]. Eosinophilic annular erythema (EAE) is a rare eosinophilic dermatosis characterized by resistance to treatment and high rate of relapse.[1] There are few reported cases in the literature and no standard treatments.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
